October 1, 1947 |
Haifa, British Mandate of Palestine (now Israel)
|Known for||Ubiquitin-mediated protein degradation|
|Notable awards||Nobel Prize in Chemistry (2004)|
Aaron Ciechanover ( pronunction (help·info) ah-hah-ROHN chee-HAH-noh-vehr[needs IPA]; אהרן צ'חנובר; born October 1, 1947) is an Israeli biologist, who won the Nobel prize in Chemistry for characterizing the method that cells use to degrade and recycle proteins using ubiquitin.
Ciechanover was born in Haifa, a year before the establishment of Israel. He is the son of Bluma (Lubashevsky), a teacher of English, and Yitzhak Ciechanover, an office worker. His family were Jewish immigrants from Poland before World War II.
He earned a master's degree in science in 1971 and graduated from Hadassah Medical School in Jerusalem in 1974. He received his doctorate in biochemistry in 1981 from the Technion – Israel Institute of Technology in Haifa before conducting postdoctoral research in the laboratory of Harvey Lodish at the Whitehead Institute at MIT from 1981-1984. He is currently a Technion Distinguished Research Professor in the Ruth and Bruce Rappaport Faculty of Medicine and Research Institute at the Technion.
As one of Israel's first Nobel Laureates in Science, he is honored in playing a central role in the history of Israel and in the history of the Technion – Israel Institute of Technology.
- Ciechanover, A., Hod, Y. and Hershko, A. (1978). A Heat-stable Polypeptide Component of an ATP-dependent Proteolytic System from Reticulocytes. Biochem. Biophys. Res. Commun. 81, 1100–1105.
- Ciechanover, A., Heller, H., Elias, S., Haas, A.L. and Hershko, A. (1980). ATP-dependent Conjugation of Reticulocyte Proteins with the Polypeptide Required for Protein Degradation. Proc. Natl. Acad. Sci. USA 77, 1365–1368.
- Hershko, A. and Ciechanover, A. (1982). Mechanisms of intracellular protein breakdown. Annu. Rev. Biochem. 51, 335–364.
Ciechanover has served on the Scientific Advisory Boards of the following companies: Rosetta Genomics (Chairman), BioLineRx, Ltd, StemRad, Ltd, Allosterix Ltd, Proteologics, Inc, MultiGene Vascular Systems, Ltd, Protalix BioTherapeutics and BioTheryX, Inc.
Ciechanover is a member of the Advisory Board of Patient Innovation, a nonprofit, international, multilingual, free venue for patients and caregivers of any disease to share their innovations.
- In 2000, Ciechanover received the Albert Lasker Award for Basic Medical Research.
- In 2003, he was awarded the Israel Prize, for biology.
- In 2004, he was awarded Nobel Prize in Chemistry for his discovery with Avram Hershko and Irwin Rose, of ubiquitin-mediated protein degradation. The ubiquitin-proteasome pathway has a critical role in maintaining the homeostasis of cells and is believed to be involved in the development and progression of diseases such as: cancer, muscular and neurological diseases, immune and inflammatory responses.
- In 2006, he was awarded the Sir Hans Krebs Medal
- "Israel Prize Official Site (in Hebrew) – Recipient’s C.V.".
- "Israel Prize Official Site (in Hebrew) – Judges' Rationale for Grant to Recipient".
- Nobel citation
- Aaron Ciechanover and Avram Hershko 2004 Nobel in Chemistry – A web article
- "Sir Hans Krebs Medal to Harald Stenmark". Oslo University Hospital. Retrieved 16 December 2014.
|Wikimedia Commons has media related to Aaron Ciechanover.|